VE-800 is under clinical development by Vedanta Biosciences and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how VE-800’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
VE-800 overview
VE-800 is under development for the treatment of solid tumors including gastric/gastroesophageal junction adenocarcinoma, microsatellite-stable colorectal cancer and metastatic melanoma. The drug candidate is consortia of live bacteria based on microbiome-derived live biotherapeutic. The drug candidate is administered by oral route. It acts by targeting CD8 cells.
Vedanta Biosciences overview
Vedanta Biosciences is a clinical-stage company which focuses on microbiome, which performs critical functions that preserve health including modulating our immune system and providing colonization resistance against infectious pathogens. Vedanta Biosciences is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of VE-800’s drug-specific PTSR and LoA scores, buy the report here.
Source link
#VE800 #Vedanta #Biosciences #Solid #Tumor #Likelihood #Approval
